Overview

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2030-04-17

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is: * Effective in improving survival * safe and tolerable

Phase:

PHASE2

Details

Lead Sponsor:

Barbara Ann Karmanos Cancer Institute

Collaborator:

THERABIONIC INC.

Treatments:

HMPL-013